• ISSN 16748301
  • CN 32-1810/R
Volume 32 Issue 4
Apr.  2018
Article Contents

Citation:

Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing rat fetal development

  • Received Date: 2018-04-17
    Accepted Date: 2018-03-23

    Fund Project: This work was funded by the following Grants:National Natural Science Foundation of China, Grant/Award Number: 81370724, 81571463 and 81401225 Innovative Research Program for Postgraduate in Higher Education Institutions of Jiangsu Province for the year 2016, Grant/Award Number: KYLX16_1111.We thank Professor Juan Li for assistance with the experiments, Professor Biyun Xu for suggestions on statistical analysis and Professor Yan Zhou for valuable discussion.

  • Preeclampsia is associated with over-activation of the innate immune system in the placenta, in which toll-like receptor 4 (TLR4) plays an essential part. With their potent anti-inflammatory effects, statins have been suggested as potential prevention or treatment of preeclampsia, although evidence remains inadequate. Herewith, we investigated whether pravastatin could ameliorate preeclampsia-like phenotypes in a previously established lipopolysaccharide (LPS)-induced rat preeclampsia model, through targeting the TLR4/NF-kB pathway. The results showed that pravastatin reduced the blood pressure [maximum decline on gestational day (GD) 12, (101.33 ± 2.49) mmHg vs. (118.3 ± 1.37) mmHg, P < 0.05] and urine protein level [maximum decline on GD9, (3,726.23 ± 1,572.86) mg vs. (1,991.03 ± 609.37) mg, P < 0.05], which were elevated following LPS administration. Pravastatin also significantly reduced the rate of fetal growth restriction in LPS-treated rats (34.10% vs. 8.99%, P < 0.05). Further pathological analyses suggested a restoration of normal spiral artery remodeling in preeclampsia rats by pravastatin treatment. These effects of pravastatin were associated with decreased TLR4/NF-kB protein levels in the placenta and IL-6/MCP-1 levels in serum. Additionally, no obvious abnormalities in fetal liver, brain, and kidney were found after administration of pravastatin. These results provide supportive evidence for use of pravastatin in preventing preeclampsia.
  • 加载中
  • 加载中

Article Metrics

Article views(382) PDF downloads(119) Cited by()

Related
Proportional views
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Pravastatin alleviates lipopolysaccharide-induced placental TLR4 over-activation and promotes uterine arteriole remodeling without impairing rat fetal development

  • 1. Drum Tower Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu 210008, China
  • 2. Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing,Jiangsu 210008, China.
Fund Project:  This work was funded by the following Grants:National Natural Science Foundation of China, Grant/Award Number: 81370724, 81571463 and 81401225 Innovative Research Program for Postgraduate in Higher Education Institutions of Jiangsu Province for the year 2016, Grant/Award Number: KYLX16_1111.We thank Professor Juan Li for assistance with the experiments, Professor Biyun Xu for suggestions on statistical analysis and Professor Yan Zhou for valuable discussion.

Abstract: Preeclampsia is associated with over-activation of the innate immune system in the placenta, in which toll-like receptor 4 (TLR4) plays an essential part. With their potent anti-inflammatory effects, statins have been suggested as potential prevention or treatment of preeclampsia, although evidence remains inadequate. Herewith, we investigated whether pravastatin could ameliorate preeclampsia-like phenotypes in a previously established lipopolysaccharide (LPS)-induced rat preeclampsia model, through targeting the TLR4/NF-kB pathway. The results showed that pravastatin reduced the blood pressure [maximum decline on gestational day (GD) 12, (101.33 ± 2.49) mmHg vs. (118.3 ± 1.37) mmHg, P < 0.05] and urine protein level [maximum decline on GD9, (3,726.23 ± 1,572.86) mg vs. (1,991.03 ± 609.37) mg, P < 0.05], which were elevated following LPS administration. Pravastatin also significantly reduced the rate of fetal growth restriction in LPS-treated rats (34.10% vs. 8.99%, P < 0.05). Further pathological analyses suggested a restoration of normal spiral artery remodeling in preeclampsia rats by pravastatin treatment. These effects of pravastatin were associated with decreased TLR4/NF-kB protein levels in the placenta and IL-6/MCP-1 levels in serum. Additionally, no obvious abnormalities in fetal liver, brain, and kidney were found after administration of pravastatin. These results provide supportive evidence for use of pravastatin in preventing preeclampsia.

    HTML

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return